Literature DB >> 1329440

Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss.

B P Lukert1, B E Johnson, R G Robinson.   

Abstract

This is a retrospective study of 15 postmenopausal or amenorrheic women aged 34-78 years who had taken prednisone for 6-108 months and were followed for 1 year while continuing to take doses of 5-15 mg/day. A total of 8 patients were treated with 0.6256 mg Premarin daily for 25 days and 5 mg/day of medroxyprogesterone on days 15-25 (ERT, group 2); 7 were followed without ERT (group 1). A group of 17 women, matched for age, were randomly selected from our computerized data base to serve as a control group (group 3), and 10 women of similar age who were taking ERT only (group 4) were selected to compare the response to ERT to that of group 2. Bone density (BD) was measured in the lumbar spine baseline and at 1 year using dual-photon or dual-energy x-ray absorptiometry. Spine density did not change significantly during the year of observation in group 1. Although BD decreased in 5 of 7 patients, the change was not significant (-0.034 +/- 0.018 g/cm2, p = 0.10). In group 2 BD increased significantly, with 7 of 8 patients showing an increase (0.037 +/- 0.011 g/cm2, p = 0.008). BD did not change significantly in the control group (0.013 +/- 0.008 g/cm2, p = 0.16). Loss of bone from the spine was significantly greater in group 1 than in controls (p = 0.02), but changes in group 2 were similar to those in the control group (p = 0.66).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329440     DOI: 10.1002/jbmr.5650070909

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  28 in total

1.  Low use of long-term hormone replacement therapy in Denmark.

Authors:  C Olesen; F H Steffensen; H T Sørensen; G L Nielsen; J Olsen; U Bergman
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

2.  Management of bone disease in patients on long term glucocorticoid therapy.

Authors:  J E Compston
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

3.  Polymyalgia rheumatica and giant cell arteritis. Consider prophylaxis for steroid induced osteoporosis.

Authors:  S Jamieson; F Thomson
Journal:  BMJ       Date:  1995-08-12

Review 4.  Prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  F Eggelmeijer
Journal:  Pharm World Sci       Date:  1998-10

5.  Prevention of glucocorticoid induced osteoporosis.

Authors:  J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

6.  Vertebral fractures and bone mineral density in idiopathic, secondary and corticosteroid associated osteoporosis in men.

Authors:  S F Evans; M W Davie
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

7.  Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.

Authors:  Jean-Pierre Devogelaer; Stefan Goemaere; Steven Boonen; Jean-Jacques Body; Jean-Marc Kaufman; Jean-Yves Reginster; Serge Rozenberg; Yves Boutsen
Journal:  Osteoporos Int       Date:  2005-10-11       Impact factor: 4.507

8.  Age and gender specific stimulation of creatine kinase specific activity by gonadal steroids in human bone-derived cells in culture.

Authors:  S Katzburg; A Ornoy; D Hendel; M Lieberherr; A M Kaye; D Somjen
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

Review 9.  Prevention and treatment of bone changes associated with exposure to glucocorticoids.

Authors:  Amy H Warriner; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

10.  The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

Authors:  H P Bhattoa; P Bettembuk; A Balogh; G Szegedi; E Kiss
Journal:  Osteoporos Int       Date:  2003-12-16       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.